According to FutureWise analysis the market for Severe Combined Immunodeficiency in 2023 is US$ 0.21 billion, and is expected to reach US$ 0.47 billion by 2031 at a CAGR of 10.60%.
In severe combined immunodeficiency (SCID), also known as Swiss-type agammaglobulinemia, multiple genetic mutations disrupt the development of functional T cells and B cells, resulting in diverse clinical presentations. The defect in antibody response in SCID is either caused by direct involvement with B lymphocytes or by improper activation of B lymphocytes due to non-functional T-helper cells. In other words, both "arms" of the adaptive immune system (B cells and T cells) are impaired due to genetic defects. The most severe form of primary immunodeficiency, SCID, can be caused by mutations in nine different genes. Bubble boy disease and bubble baby disease are also called bubble boy and bubble baby diseases because its victims are extremely susceptible to infectious diseases and some of them, such as David Vetter, live in sterile environments. It is characterized by an immune system that is so compromised that it is considered almost nonexistent. Early in life, SCID patients often suffer from severe bacterial, viral, or fungal infections, which can lead to interstitial lung disease, chronic diarrhea, and failure to thrive. Ear infections, pneumonia caused by Pneumocystis jirovecii (previously carinii), and oral candidiasis are common. If left untreated, these babies usually die within a year unless they have received successful stem cell transplants or gene therapy in clinical trials. A rise in healthcare expenditures and the prevalence of severe combined immunodeficiency are two of the main factors driving the market's growth. A number of factors will contribute to the growth of the severe combined immunodeficiency market, including technological advancements in screening techniques, increased investments by leading players, and increasing initiatives from public and private organizations to raise awareness about diagnosis and screening. A growing adoption of stem cell therapy, gene therapy, and other therapies will also cushion the market growth rate due to the availability of drugs and immune-related treatments. During the forecast period, the severe combined immunodeficiency market will benefit from research and development activities and emerging new markets.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Severe Combined Immunodeficiency Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Severe Combined Immunodeficiency Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.